Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 16

1.

A complications-based clinical staging of obesity to guide treatment modality and intensity.

Daniel S, Soleymani T, Garvey WT.

Curr Opin Endocrinol Diabetes Obes. 2013 Oct;20(5):377-88. doi: 10.1097/01.med.0000433067.01671.f5. Review.

2.

Short-term effects of sibutramine on mineral status and selected biochemical parameters in obese women.

Suliburska J, Bogdański P, Szulińska M, Pupek-Musialik D.

Biol Trace Elem Res. 2012 Nov;149(2):163-70. doi: 10.1007/s12011-012-9425-6. Epub 2012 Apr 27.

3.

Effectiveness of a psychosocial weight management program for individuals with schizophrenia.

Niv N, Cohen AN, Hamilton A, Reist C, Young AS.

J Behav Health Serv Res. 2014 Jul;41(3):370-80. doi: 10.1007/s11414-012-9273-3.

4.

Serotonin and blood pressure regulation.

Watts SW, Morrison SF, Davis RP, Barman SM.

Pharmacol Rev. 2012 Apr;64(2):359-88. doi: 10.1124/pr.111.004697. Epub 2012 Mar 8. Review.

5.

Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide.

Astrup A, Carraro R, Finer N, Harper A, Kunesova M, Lean ME, Niskanen L, Rasmussen MF, Rissanen A, Rössner S, Savolainen MJ, Van Gaal L; NN8022-1807 Investigators.

Int J Obes (Lond). 2012 Jun;36(6):843-54. doi: 10.1038/ijo.2011.158. Epub 2011 Aug 16. Erratum in: Int J Obes (Lond). 2012 Jun;36(6):890. Int J Obes (Lond). 2013 Feb;37(2):322.

6.

Tackling obesity: new therapeutic agents for assisted weight loss.

Karam J, McFarlane S.

Diabetes Metab Syndr Obes. 2010 Apr 26;3:95-112.

7.

Present and future: pharmacologic treatment of obesity.

Glandt M, Raz I.

J Obes. 2011;2011:636181. doi: 10.1155/2011/636181. Epub 2011 Feb 8.

8.
9.

Pharmacotherapies for obesity: past, current, and future therapies.

Ioannides-Demos LL, Piccenna L, McNeil JJ.

J Obes. 2011;2011:179674. doi: 10.1155/2011/179674. Epub 2010 Dec 12.

10.

Predictors of Psychological Well-Being during Behavioral Obesity Treatment in Women.

Vieira PN, Mata J, Silva MN, Coutinho SR, Santos TC, Minderico CS, Sardinha LB, Teixeira PJ.

J Obes. 2011;2011:936153. doi: 10.1155/2011/936153. Epub 2010 Nov 1.

11.

The use of sibutramine in the management of obesity and related disorders: an update.

Tziomalos K, Krassas GE, Tzotzas T.

Vasc Health Risk Manag. 2009;5(1):441-52. Review.

12.

The appropriateness of routine medication treatment for schizophrenia.

Young AS, Niv N, Cohen AN, Kessler C, McNagny K.

Schizophr Bull. 2010 Jul;36(4):732-9. doi: 10.1093/schbul/sbn138. Epub 2008 Nov 7.

13.

Industry funding and the reporting quality of large long-term weight loss trials.

Thomas O, Thabane L, Douketis J, Chu R, Westfall AO, Allison DB.

Int J Obes (Lond). 2008 Oct;32(10):1531-6. doi: 10.1038/ijo.2008.137. Epub 2008 Aug 19. Review.

14.

Diabetes and hypertension in severe obesity and effects of gastric bypass-induced weight loss.

Sugerman HJ, Wolfe LG, Sica DA, Clore JN.

Ann Surg. 2003 Jun;237(6):751-6; discussion 757-8.

15.

Obesity drug sibutramine (Meridia): hypertension and cardiac arrhythmias.

Wooltorton E.

CMAJ. 2002 May 14;166(10):1307-8. No abstract available.

16.

Extracts from "Clinical Evidence". Obesity.

Arterburn D, Noël PH.

BMJ. 2001 Jun 9;322(7299):1406-9. No abstract available.

Supplemental Content

Support Center